Laboratory antimicrobial resistance surveillance: extend spectrum beta lactamase (ESBL) producing E. coli by Mobasherizadeh, S et al.
POSTER PRESENTATION Open Access
Laboratory antimicrobial resistance surveillance:
extend spectrum beta lactamase (ESBL)
producing E. coli
S Mobasherizadeh
1*, S Jalalpoor
2, A Ebneshahidi
3, L Ghaedi
1
From International Conference on Prevention & Infection Control (ICPIC 2011)
Geneva, Switzerland. 29 June – 2 July 2011
Introduction / objectives
This study aims to investigate the prevalence of ESBL
producing E.coli in urinary tract nosocomial and com-
munity acquired infections of Isfahan selected hospitals.
Methods
The present study was performed at four tertiary care
hospitals in Isfahan, Iran. During a 14 month period (Jun,
7
th,2008 to July,6
th ,2010).690 ofÂ E.coli isolated from
urinary tract infection were studied. 425 of E.coli isolated
from community acquired and 265 isolated from nosoco-
mial urinary tract infection were evaluated. Standard
microbiological methods were performed(according to
CLSI 2006). In order to validate the extended-spectrum
beta-lactamases (ESBLs) producing strains were used by
disk diffusion method. The collected data was analyzed
thorough whonet 5.6 software.
Results
The prevalence of ESBLs producing E.coli isolated from
community acquired urinary tract infection came out to
be 17% and 58% for urinary tract nosocomial infection
respectively(P<0.001).The antibiotic resistance rates of iso-
lated in nosocomial and community UTIs were 94.9% and
84.4% to ampicillin.(P<0.01),59.4% and 19.7% to ceftazi-
dime, 64.2% and 19.8% to cefotaxime, 62.5% and 12.2% to
ceftizoxime 60% and 18.6% to gentamicin.(P<0.001), 17%
and 8.2% to amikacin , and 40.8% to Nalidixic acid, 23.1%
and 10.2% to nitrofurantoin,47.5% and 31.4% to ciproflox-
acin and 84.4% and 60.1% to trimethoprim/sulfamethoxa-
zole (p<0.005).
Conclusion
Establish systems for monitoring antimicrobial resis-
tance in hospitals and the community and link these
findings to resistance and disease surveillance data is
fundamental to developing treatment guidelines accu-
rately and to assessing the effectiveness of interventions
appropriately.
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